DesArg10[Hoe 140] is a potent B1 bradykinin antagonist
Wirth, K.J.; Wiemer, G.; Schölkens, B.A.
Agents and Actions. Supplements 38: 406-413
1992
ISSN/ISBN: 0379-0363 PMID: 1334341 Document Number: 388026
DesArg10[Hoe 140] and Des(D-Arg1, Arg10)[Hoe 140], desArg10-analogs of the potent and stable B2 bradykinin (BK) receptor antagonist Hoe 140 were found to be potent and stable antagonists of the B1 receptor in vitro and in vivo. They were, however, less selective than DesArg9[Leu8]BK, the metabolically unstable B1 prototype antagonist. Surprisingly, Hoe 140, which behaved as a pure B2 antagonist in several smooth muscle preparations, had a considerable inhibitory effect against the B1 agonist DesArg9-BK in bovine aortic endothelial cells. This finding for the first time suggests that B1 receptors are heterogenous.
Document emailed within 1 workday
Related Documents
Wilson, D.D.; de Garavilla, L.; Kuhn, W.; Togo, J.; Burch, R.M.; Steranka, L.R. 1989: D-Arg-[Hyp3-D-Phe7]-bradykinin, a bradykinin antagonist, reduces mortality in a rat model of endotoxic shock Circulatory Shock 27(2): 93-101Sethi, O.P.; Naik, K. 1979: Xanthotoxol (XT) - a potent 5-HT antagonist Indian Journal of Physiology and Pharmacology 23(2): 142-143
Debeljuk, L.; Schally, A.V. 1986: Antifertility effects of a potent LH-RH antagonist in male and female rats International Journal of Fertility 31(4): 284-292
Ligneau, X.; Lin, J.; Vanni-Mercier, G.; Jouvet, M.; Muir, J.L.; Ganellin, C.R.; Stark, H.; Elz, S.; Schunack, W.; Schwartz, J. 1998: Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist Journal of Pharmacology and Experimental Therapeutics 287(2): 658-666
Pendley, C.E.; Fitzpatrick, L.R.; Capolino, A.J.; Davis, M.A.; Esterline, N.J.; Jakubowska, A.; Bertrand, P.; Guyon, C.; Dubroeucq, M.C.; Martin, G.E. 1995: RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat Journal of Pharmacology and Experimental Therapeutics 273(3): 1015-1022
Bellemann, P.; Ferry, D.; Lübbecke, F.; Glossman, H. 1981: 3H]-Nitrendipine, a potent calcium antagonist, binds with high affinity to cardiac membranes Arzneimittel-Forschung 31(12): 2064-2067
Cutler, G.B.; Sauer, M.A.; Loriaux, D.L. 1979: SC 25152: a potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone Journal of Pharmacology and Experimental Therapeutics 209(1): 144-146
Wilkinson, A.; Courtney, M.; Westlind-Danielsson, A.; Hallnemo, G.; Akerman, K.E. 1994: Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow Journal of Pharmacology and Experimental Therapeutics 271(3): 1314-1319
Kadowaki, M.; Nagakura, Y.; Tomoi, M.; Mori, J.; Kohsaka, M. 1993: Effect of FK1052, a potent 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptor dual antagonist, on colonic function in vivo Journal of Pharmacology and Experimental Therapeutics 266(1): 74-80
Katz, L.B.; Scott, C.K.; Shriver, D.A. 1986: Pharmacological comparison of ORF 17910, a potent, long-acting histamine H2-receptor antagonist, to cimetidine and ranitidine Journal of Pharmacology and Experimental Therapeutics 238(2): 587-593
Adkison, K.K.; Halm, K.A.; Shaffer, J.E.; Drewry, D.; Sinhababu, A.K.; Berman, J. 1998: Discovery of a potent and selective alpha 1A antagonist. Utilization of a rapid screening method to obtain pharmacokinetic parameters Pharmaceutical Biotechnology 11: 423-443
Bonacchi, G.; Agostini, O.; Fedi, M.; Bacciarelli, C.; Boni, P.; Castellucci, A.; Perretti, F.; Manzini, S. 1988: Resolution and pharmacological properties of the enantiomers of the potent alpha-adrenoceptor antagonist 1-[2-ethoxy-2-(3'-pyridyl)ethyl]-4-(2'-methoxy-phenyl)piperazine Arzneimittel-Forschung 38(5): 650-654
Cohen, M.L.; Robertson, D.W.; Bloomquist, W.E.; Wilson, H.C. 1992: LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis Journal of Pharmacology and Experimental Therapeutics 261(1): 202-208
Martin, P.L.; Wysocki, R.J.; Barrett, R.J.; May, J.M.; Linden, J. 1996: Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors Journal of Pharmacology and Experimental Therapeutics 276(2): 490-499
Belardinelli, L.; Shryock, J.C.; Zhang, Y.; Scammells, P.J.; Olsson, R.; Dennis, D.; Milner, P.; Pfister, J.; Baker, S.P. 1995: 1,3-Dipropyl-8-[2-(5,6-epoxy)norbornyl]xanthine, a potent, specific and selective A1 adenosine receptor antagonist in the guinea pig heart and brain and in DDT1MF-2 cells Journal of Pharmacology and Experimental Therapeutics 275(3): 1167-1176
Takemoto, Y.; Yuki, H.; Nishida, A.; Ito, H.; Kobayashi-Uchida, A.; Takinami, Y.; Akuzawa, S.; Ohta, M.; Satoh, M.; Semple, G.; Miyata, K. 1998: Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula Arzneimittel-Forschung 48(4): 403-407
Liebmann, C.; Bossé, R.; Escher, E. 1994: Discrimination between putative bradykinin B2 receptor subtypes in guinea pig ileum smooth muscle membranes with a selective, iodinatable, bradykinin analogue Molecular Pharmacology 46(5): 949-956
Rodríguez de Fonseca, F.; Rubio, P.; Menzaghi, F.; Merlo-Pich, E.; Rivier, J.; Koob, G.F.; Navarro, M. 1996: Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats Journal of Pharmacology and Experimental Therapeutics 276(1): 56-64
Suzuki, N.; Matsunaga, T.; Kanaho, Y.; Nozawa, Y. 1993: The mechanism of bradykinin-induced arachidonic acid release in osteoblast-like MC3T3-E1 cells phospholipase A2 activation by bradykinin and its regulation by protein kinase C and calcium Nihon Seikeigeka Gakkai Zasshi 67(10): 935-943
Sekiguchi, H.; Hamada, K.; Taga, F.; Nishino, K. 1993: Effects of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl] urea with potent gastric mucosal protective activity on acute gastric lesions and duodenal ulcers in rats Arzneimittel-Forschung 43(2): 134-138